Cargando…

Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota

PURPOSE: To address whether Curcumin has synergistic effect with cytarabine (Ara-C) in treating acute myeloid leukemia (AML). METHODS: A xenograft AML mouse model was established by injecting HL-60 cells into tail vein of mice to assess the function of Curcumin. Mononuclear cells (MNCs) isolated fro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Junmin, Luo, Wei, Chen, Qiuru, Chen, Xing, Zhou, Gang, Sun, Hongbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807457/ https://www.ncbi.nlm.nih.gov/pubmed/35066694 http://dx.doi.org/10.1007/s00280-021-04385-0

Ejemplares similares

DUSP1 Signaling Pathway Regulates Cytarabine Sensitivity in Acute Myeloid Leukemia
por: Sun, Huali, et al.
Publicado: (2023)

Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine
por: Visser, Nienke, et al.
Publicado: (2021)

Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
por: Momparler, Richard L
Publicado: (2013)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia
por: Zhou, Shiyong, et al.
Publicado: (2017)

Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance
por: Åbacka, Hannah, et al.
Publicado: (2021)

Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia
por: Anderson, Rebecca, et al.
Publicado: (2022)

Heteronemin, a marine natural product, sensitizes acute myeloid leukemia cells towards cytarabine chemotherapy by regulating farnesylation of Ras
por: Saikia, Minakshi, et al.
Publicado: (2018)

A clinical report on high‑dose cytarabine therapy for children with acute myeloid leukemia
por: Wu, Ziliang, et al.
Publicado: (2022)

Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia
por: Leonard, Sarah M., et al.
Publicado: (2014)

Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience
por: Bashir, Yasir, et al.
Publicado: (2015)

Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells
por: Li, Peng, et al.
Publicado: (2016)

Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia
por: Khokhlatchev, Andrei V., et al.
Publicado: (2022)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia
por: Canaani, Jonathan, et al.
Publicado: (2020)

Curcumin induces apoptosis by inhibiting BCAT1 expression and mTOR signaling in cytarabine-resistant myeloid leukemia cells
por: Tseng, Yu-Hsin, et al.
Publicado: (2021)

Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia
por: Wei, Hui, et al.
Publicado: (2020)

miR-134 increases the antitumor effects of cytarabine by targeting Mnks in acute myeloid leukemia cells
por: Chen, Kankan, et al.
Publicado: (2018)

Safety and Feasibility of Outpatient High Dose Cytarabine for Acute Myeloid Leukemia in the Brazilian Amazon
por: Rodrigues, Amanda Lopes Maia, et al.
Publicado: (2020)

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
por: Nishi, Rie, et al.
Publicado: (2020)

Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo
por: Serhan, Nizar, et al.
Publicado: (2020)

Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
por: Heo, Sook-Kyoung, et al.
Publicado: (2020)

Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia
por: Liu, Qingguo, et al.
Publicado: (2020)

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
por: Konopleva, Marina Y., et al.
Publicado: (2022)

Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia
por: Morales, María Luz, et al.
Publicado: (2023)

CD157 signaling promotes survival of acute myeloid leukemia cells and modulates sensitivity to cytarabine through regulation of anti-apoptotic Mcl-1
por: Yakymiv, Yuliya, et al.
Publicado: (2021)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

MicroRNA-143 sensitizes acute myeloid leukemia cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy
por: Zhang, Hao, et al.
Publicado: (2020)

High-Dose Cytarabine in Acute Myeloid Leukemia Treatment: A Systematic Review and Meta-Analysis
por: Li, Wei, et al.
Publicado: (2014)

Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells
por: Bista, Ranjan, et al.
Publicado: (2017)

Observation of clinical efficacy and toxic and side effects of pirarubicin combined with cytarabine on acute myeloid leukemia
por: Lv, Suqin, et al.
Publicado: (2019)

Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia
por: Hatzl, Stefan, et al.
Publicado: (2020)

Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia
por: Barwe, Sonali P., et al.
Publicado: (2022)

Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review
por: Arwanih, Elly Y, et al.
Publicado: (2022)

Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy
por: Rodríguez-Macías, Gabriela, et al.
Publicado: (2023)

Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia
por: Lee, Julia S., et al.
Publicado: (2023)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

Nrf2 overexpression increases the resistance of acute myeloid leukemia to cytarabine by inhibiting replication factor C4
por: Hu, Tianzhen, et al.
Publicado: (2022)

Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia
por: Yan, Han, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_f4abvo2mc0v2cjcdsumf86sv25